RC
DGX icon

Rexford Capital’s Quest Diagnostics DGX Stock Holding History

Rexford Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.2K Hold
200
– – 0.03% 241
2025
Q4 		$34.7K Hold
200
– – 0.03% 247
2025
Q3 		$38.1K Hold
200
– – 0.03% 241
2025
Q2 		$35.9K Buy
+200
New +$34.7K 0.03% 243

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Rexford Capital's DGX Position: Q1 2026 in Review

Rexford Capital held its Quest Diagnostics (DGX) position steady in Q1 2026 at 200 shares worth $39.2K. The position accounts for 0.03% of the portfolio, ranked #241.

Rexford Capital first reported a position in DGX in Q2 2025 and has held it in 4 quarters since. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Rexford Capital held 200 shares of Quest Diagnostics worth $39.2K as of Q1 2026.
  • Rexford Capital left its Quest Diagnostics share count unchanged in Q1 2026.
  • Quest Diagnostics made up 0.03% of Rexford Capital's portfolio in Q1 2026, its #241 holding.
  • Rexford Capital first reported a position in Quest Diagnostics in Q2 2025 and has held it in 4 quarters since.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Rexford Capital's 13F filing for Q1 2026, filed 24 Apr 2026.